TheraCryf plc (LSE:TCF) disclosed that it received and rejected a non-binding proposal to acquire its lead neuropsychiatry programmes, as it reported a wider post-tax loss of £3.5m for the year to 31 March 2026 and a post-period fundraise that it says extends its cash runway to the first quarter of 2027.
What was announced
TheraCryf (LSE:TCF), an AIM-quoted biotechnology company developing medicines for addiction and neuropsychiatric disorders, published its final results for the year to 31 March 2026 on 28 September 2026.
The company said that after the year end it received a non-binding Acquisition proposal from an unnamed party for its lead neuropsychiatry assets, the Ox-1 orexin-1 receptor antagonist programme and its dopamine transporter (DAT) programme. The board rejected the approach on the basis that it did not reflect the value of the company's technology. Chair Dr Alastair Smith said the proposal reflected commercial and clinical interest in the assets. This was a proposal for specific Assets rather than an offer for the company, and no price or other terms were disclosed.
The numbers
The post-tax loss increased to £3.5m from £1.9m in the previous year, as R&D spending rose to £1.5m from £0.3m. Operating expenses, excluding share-based payments, were £3.5m, and the operating cash outflow was £2.7m (£2.4m). The loss per share fell to 0.16p from 0.36p, while the weighted average number of shares rose to about 2.15 billion from about 538 million.
Cash and short-term investments were £1.5m at 31 March 2026, down from £4.1m a year earlier, and net assets fell to £2.7m from £5.9m.
In September 2026 TheraCryf raised £1.05m gross at 0.18p a share through the placing of 416,388,888 shares and the subscription of 166,944,440 shares, taken up by existing and new investors. The company said this extends its cash runway to the first quarter of 2027. The Going Concern statement flags a material uncertainty: additional funding will be required within the 12-month assessment period, and no binding funding arrangements were in place at the approval date, although the directors expect funding can be obtained.
Programme progress
For Ox-1, which is being developed for addiction indications including alcohol and substance use disorders and binge eating, the company manufactured 10.6kg of drug substance for toxicology studies and selected the final formulation. GLP toxicology dose-range-finding work was completed with no adverse observations at maximum doses. Patents were granted in South Korea and Canada, and an additional process Patent filing is intended to extend protection to 2046.
After the year end, a 2.57kg batch of GMP-grade drug substance was completed ahead of schedule. The first-species GLP toxicology study has been completed and, according to the company, demonstrated a "wide Margin of safety", while a second-species study is under way.
The DAT modulator programme, aimed at fatigue in conditions such as multiple sclerosis, chemotherapy-related fatigue and narcolepsy, is the subject of partnering discussions. The legacy SFX-01 glioblastoma programme is grant-funded, and disputes with partner Stalicla SA are ongoing.
Edward Wardle joined the board as a non-executive director, nominated by Northern Standard Ltd, a significant shareholder.
Chief Executive Dr Huw Jones said the company is "approaching more value inflection points ahead of first-in-human trials". He cited a substance use disorder market of about US$42bn, which the company cites as forecast to exceed US$71bn by 2034.
What to watch next
TheraCryf expects final GLP toxicology data in the fourth quarter of 2026. It is then targeting regulatory submissions and approval for a Phase 1 study in Australia, alongside discussions with potential partners; Dr Smith said the data sets are intended to "attract major pharmaceutical partners or acquirers." The timing of further funding beyond the first quarter of 2027 is not disclosed.






Please wait processing your request...